Loading
Taiwanese oncologist who led the Asia-Pacific sorafenib trial and co-led IMbrave150, the immunotherapy standard for liver cancer.
Ann-Lii Cheng led the Asia-Pacific trial that confirmed sorafenib's benefit in hepatitis B-driven hepatocellular carcinoma and was co-principal investigator of IMbrave150, which established atezolizumab plus bevacizumab as first-line therapy. He has led or co-led most major HCC systemic therapy trials in Asia, including REFLECT (lenvatinib) and the adjuvant IMbrave050 study.
Shares IMbrave150, IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer, Atezolizumab, PD-L1 and the tag hcc.
Shares IMbrave150, IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer, Atezolizumab, Hepatocellular carcinoma.
Shares REFLECT, Hepatocellular carcinoma and the tag hcc.
Shares Atezolizumab, PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares Hepatocellular carcinoma and the tags hcc, immunotherapy.
Shares IMbrave050, IMbrave150, IMbrave150: atezolizumab plus bevacizumab replaces sorafenib as first treatment for advanced liver cancer, Atezolizumab.
Shares Atezolizumab, PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.
Shares PD-L1, Immune checkpoint inhibitors and the tag immunotherapy.